Short description: Chemical compound
CBiPES |
Clinical data |
---|
ATC code | |
---|
Identifiers |
---|
N-(4'-cyano-[1,1'-biphenyl]-3-yl-N-(3-pyridinylmethyl)ethanesulfonamide
|
CAS Number | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
ChemSpider | |
---|
UNII | |
---|
Chemical and physical data |
---|
Formula | C21H19N3O2S |
---|
Molar mass | 377.46 g·mol−1 |
---|
3D model (JSmol) | |
---|
N#Cc1ccc(cc1)-c(ccc2)cc2N(S(=O)(=O)CC)Cc3cccnc3
|
InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3 Key:HDVYXILCBYGKGU-UHFFFAOYSA-N
|
CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR2 receptors in schizophrenia and related disorders.[1][2][3]
References
- ↑ "Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology 179 (1): 271–83. April 2005. doi:10.1007/s00213-004-2099-9. PMID 15717213.
- ↑ "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology 58 (3): 632–9. March 2010. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716.
- ↑ "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology 66: 264–73. March 2013. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090.
| Original source: https://en.wikipedia.org/wiki/CBiPES. Read more |